Literature DB >> 12901034

Evaluation of the appropriate use of albumin in adult and pediatric patients.

Mario Tanzi1, Melinda Gardner, Michelle Megellas, Steven Lucio, Maryann Restino.   

Abstract

The appropriateness of albumin use and baseline albumin usage patterns were studied. Institutional practice patterns regarding the use of albumin were compared to criteria established by an independent expert panel. Fifty-three institutions, all of which were members of VHA or the University Health-System Consortium, participated in the evaluation. Investigators collected data over an eight-week period from the medical records, pharmacy records, and hospital billing data of adult (18 years of age or older) and pediatric (age 1-17 years) patients for whom albumin was prescribed. Data collected included patient-specific information, the prescribing physician's specialty area, patient location (level of care) when albumin was prescribed, primary reasons for prescribing albumin, and details of albumin use. Data were collected for 1649 adult and 23 pediatric patients. Albumin was prescribed inappropriately in 57.8% and appropriately in 28.2% of adults; appropriateness of use was unknown in 14% of the patients reviewed. The most common indication for albumin use was hypotension/hypovolemia (23.9%), followed by bypass-pump priming (16.3%), intradialytic blood pressure support (9.6%), and serum albumin values less than 2 g/dL (8.6%). Albumin was prescribed inappropriately 100% of the time when used for intradialytic blood pressure support, low serum albumin values, and acute respiratory distress syndrome. The most appropriate use of albumin occurred in patients with postsurgical hypotension and hypovolemia (67.8%), nephrotic syndrome (79.3%), non-hemorrhagic shock (44.3%), hemorrhagic shock (51.9%), and cirrhosis and paracentesis (31.3%). Albumin was inappropriately prescribed for 57.8% of adult patients and 52.2% of pediatric patients. The mean number of total grams used by patients receiving albumin appropriately was similar to those patients inappropriately receiving albumin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12901034     DOI: 10.1093/ajhp/60.13.1330

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  14 in total

Review 1.  Clinical use of albumin.

Authors:  Paolo Caraceni; Manuel Tufoni; Maria Elena Bonavita
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

2.  AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update.

Authors:  Paolo Caraceni; Paolo Angeli; Daniele Prati; Mauro Bernardi; Pierluigi Berti; Francesco Bennardello; Francesco Fiorin; Pierluigi Piccoli
Journal:  Blood Transfus       Date:  2020-12-18       Impact factor: 3.443

3.  How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure.

Authors:  Federica Mirici-Cappa; Paolo Caraceni; Marco Domenicali; Ernesto Gelonesi; Barbara Benazzi; Giacomo Zaccherini; Franco Trevisani; Cristina Puggioli; Mauro Bernardi
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

4.  Hyperoncotic Albumin Reduces Net Fluid Loss Associated With Hemodialysis.

Authors:  Mitchell S Buckley; Brian L Erstad; Jake M Lansburg; Sumit K Agarwal
Journal:  Hosp Pharm       Date:  2019-02-04

5.  Drug utilization evaluation of albumin in a teaching hospital of Mashhad, Iran: an interventional pre-post design study.

Authors:  Farzaneh Zolfagharian; Saba Ghazanfari; Sepideh Elyasi; Paria Iraji; Mohammad Reza Saberi; Nasser Vahdati-Mashhadian; Amir Hooshang Mohammadpour
Journal:  Int J Clin Pharm       Date:  2017-05-24

6.  Key Controversies in Colloid and Crystalloid Fluid Utilization.

Authors:  Erin N Frazee; David D Leedahl; Kianoush B Kashani
Journal:  Hosp Pharm       Date:  2015-06

7.  Human albumin administration in subarachnoid hemorrhage: results of an international survey.

Authors:  Jose I Suarez; Renee H Martin; Eusebia Calvillo; David Zygun; Oliver Flower; George K Wong; Eric M Bershad; Chethan P Venkatasubba Rao; Alexandros Georgiadis; Draga Jichici; Peter D Leroux
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

8.  AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis.

Authors:  Paolo Caraceni; Paolo Angeli; Daniele Prati; Mauro Bernardi; Giancarlo M Liumbruno; Francesco Bennardello; Pierluigi Piccoli; Claudio Velati
Journal:  Blood Transfus       Date:  2016-01       Impact factor: 3.443

9.  Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan.

Authors:  Isao Sakaida; Koji Nakajima; Kiwamu Okita; Masatsugu Hori; Tohru Izumi; Masaya Sakurai; Yoshiyuki Shibasaki; Sayaka Tachikawa; Hidetsugu Tsubouchi; Hiromi Oka; Hiroyuki Kobayashi
Journal:  J Gastroenterol       Date:  2015-02-18       Impact factor: 7.527

10.  The evaluation of albumin utilization in a teaching university hospital in iran.

Authors:  Zahra Jahangard-Rafsanjani; Mohammad Reza Javadi; Hassan Torkamandi; Sara Alahyari; Azita Hajhossein Talasaz; Kheirollah Gholami
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.